WuXi Biologics Expands U.S. Footprint

WuXi Biologics and the Worcester Business Development Corporation (WBDC) have signed a land deal for WuXi Biologics’ clinical and commercial manufacturing facility in Worcester at The Reactory, a 46-acre master-planned biomanufacturing campus. The approximately 107,000-square-foot, two-story facility will be operational in 2022 and create 150 new jobs.         

 
“As the central Massachusetts biotech community continues its growth, WuXi Biologics’ arrival in Worcester will strengthen the sector and lead to ongoing economic development,” said Lt. Governor Karyn Polito. “Years of planning and collaboration to transform an unused property into a biomanufacturing hub has led to this exciting announcement today and I appreciate the commitment of so many to making this a reality.”
 
Worcester City Manager Edward M. Augustus, Jr., said, “This signing solidifies our city’s proud role as an anchor in the state’s biotech corridor. It signals not only what we currently have to offer in the life sciences sector, but also how much potential we have for the future.”
           
Craig Blais, the president and chief executive officer of the WBDC, said, “WuXi Biologics’ decision to locate its first U.S. biomanufacturing facility in Worcester at The Reactory confirms the value of Worcester’s strong life sciences ecosystem. We expect other biotech manufacturers will soon follow their lead.”
 
“We are proud to join the Worcester community and greater region as a tenant of The Reactory, and I thank the city of Worcester for its collaboration,” said Chris Chen, chief executive officer, WuXi Biologics. “Drawing from the talented workforce and impressive biotech network in Massachusetts, we stand ready and able to help our global partners advance their innovative and life-saving ideas. Together, I am confident that we have much to contribute to the biologics industry and patients worldwide.”